Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single-ascending-dose study of ACT-462206 in healthy men
NL-OMON35433Phase 1Active, not recruiting
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Nov 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ACT-462206 in Insomnia and sleep disorder (3 arms), sponsored by Actelion Pharmaceuticals Ltd. Primary endpoints: Vital signs and body weight, ECG variables and 11 more. Started Nov 2011; status: active, not recruiting.
02
Drugs
ACT-462206
03
Conditions
Insomniasleep disorder
Beyond the preview
Go deeper on NL-OMON35433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35433.